MicroRNA‑324‑5p suppresses the migration and invasion of MM cells by inhibiting the SCFβ‑TrCP E3 ligase

Zhang,Lannan; Liu,Dong; Tang,Bo; Xu,Aoshuang; Huang,Haifan; Su,Yan; Xu,Jian; Deng,Jun; Tang,Liang; Sun,Chunyan; Hu,Yu

doi:10.3892/ol.2018.9245

MicroRNA‑324‑5p suppresses the migration and invasion of MM cells by inhibiting the SCFβ‑TrCP E3 ligase

Authors:
- Lannan Zhang
- Dong Liu
- Bo Tang
- Aoshuang Xu
- Haifan Huang
- Yan Su
- Jian Xu
- Jun Deng
- Liang Tang
- Chunyan Sun
- Yu Hu
View Affiliations

Affiliations: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: August 1, 2018 https://doi.org/10.3892/ol.2018.9245
Pages: 5331-5338

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple myeloma (MM) is a cytogenetically heterogeneous malignancy of plasma cells in bone marrow. Among the cytogenetic abnormalities of MM, del(17p) is a well‑recognized high‑risk genetic lesion associated with the late stage and progression of the disease. MicroRNA (miR)‑324‑5p, located at 17p13.1, was identified to be involved in the dysregulation of a number of types of malignant disease. However, whether miR‑324‑5p is associated with the development and progression of MM remains unknown. In the present study, the expression status of miR‑324‑5p in MM, and its effect on the migratory and invasive ability of MM cells were investigated. Using ubiquitination pathway polymerase chain reaction array, the inhibitory effect of miR‑324‑5p on the ubiquitinated proteins was investigated. It was identified that miR‑324‑5p levels were decreased in samples from patients with MM and MM cell lines. Increased expression of miR‑324‑5p by transfection of miR‑324‑5p mimic suppressed the proliferative, migratory and invasive abilities of MM.1R cells. Furthermore, increased expression of miR‑324‑5p in MM.1R cells inhibited the ubiquitination pathway and decreased the levels of ubiquitination‑associated proteins, particularly the Skp1‑Cullin1‑F‑box β‑transducin repeat‑containing protein (SCFβ‑TrCP) E3 ligase. In addition, the results of the present study demonstrated that the SCFβ‑TrCP E3 ligase may contribute to the suppression of MM cell motility by inhibiting the expression of metastasis‑associated genes, including metastasis suppressor 1. In conclusion, the results of the present study suggested that miR‑324‑5p may act as a tumor suppressor by impairing the motility of MM cells by suppressing the ubiquitination pathway.

View Figures

View References

1	Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, et al: Genetic aberrations and survival in plasma cell leukemia. Leukemia. 22:1044–1052. 2008. View Article : Google Scholar : PubMed/NCBI
2	Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, et al: Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 27:780–791. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, et al: Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 356:2582–2590. 2007. View Article : Google Scholar : PubMed/NCBI
4	Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, et al: Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res. 64:1546–1558. 2004. View Article : Google Scholar : PubMed/NCBI
5	Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, et al: Genetic abnormalities and survival in multiple myeloma: The experience of the intergroupe francophone du myelome. Blood. 109:3489–3495. 2007. View Article : Google Scholar : PubMed/NCBI
6	Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, Paganelli A, Di Marcotullio L, Caffarelli E, Screpanti I, et al: Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 27:2616–2627. 2008. View Article : Google Scholar : PubMed/NCBI
7	Veigaard C and Kjeldsen E: Exploring the genome-wide relation between copy number status and microRNA expression. Genomics. 104:271–278. 2014. View Article : Google Scholar : PubMed/NCBI
8	Cao L, Xie B, Yang X, Liang H, Jiang X, Zhang D, Xue P, Chen D and Shao Z: MiR-324-5p suppresses hepatocellular carcinoma cell invasion by counteracting ECM degradation through post-transcriptionally downregulating ETS1 and SP1. PLoS One. 10:e01330742015. View Article : Google Scholar : PubMed/NCBI
9	Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K and Van Valckenborgh E: Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget. 7:6521–6537. 2016. View Article : Google Scholar : PubMed/NCBI
10	Lee EK and Diehl JA: SCFs in the new millennium. Oncogene. 33:2011–2018. 2014. View Article : Google Scholar : PubMed/NCBI
11	Lau AW, Fukushima H and Wei W: The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed). 17:2197–2212. 2012. View Article : Google Scholar : PubMed/NCBI
12	Wang H, Maitra A and Wang H: The emerging roles of F-box proteins in pancreatic tumorigenesis. Semin Cancer Biol. 36:88–94. 2016. View Article : Google Scholar : PubMed/NCBI
13	Uddin S, Bhat AA, Krishnankutty R, Mir F, Kulinski M and Mohammad RM: Involvement of F-BOX proteins in progression and development of human malignancies. Semin Cancer Biol. 36:18–32. 2016. View Article : Google Scholar : PubMed/NCBI
14	Sharma R, Williams PJ, Gupta A, McCluskey B, Bhaskaran S, Muñoz S and Oyajobi BO: A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. Oncotarget. 6:21589–21602. 2015. View Article : Google Scholar : PubMed/NCBI
15	Bompard G, Sharp SJ, Freiss G and Machesky LM: Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B. J Cell Sci. 118:5393–5403. 2005. View Article : Google Scholar : PubMed/NCBI
16	Ma S, Guan XY, Lee TK and Chan KW: Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. Hum Pathol. 38:1201–1206. 2007. View Article : Google Scholar : PubMed/NCBI
17	Parr C and Jiang WG: Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer. 45:1673–1683. 2009. View Article : Google Scholar : PubMed/NCBI
18	Du P, Ye L, Ruge F, Yang Y and Jiang WG: Metastasis suppressor-1, MTSS1, acts as a putative tumour suppressor in human bladder cancer. Anticancer Res. 31:3205–3212. 2011.PubMed/NCBI
19	Yu D, Zhan XH, Zhao XF, Williams MS, Carey GB, Smith E, Scott D, Zhu J, Guo Y, Cherukuri S, et al: Mice deficient in MIM expression are predisposed to lymphomagenesis. Oncogene. 31:3561–3568. 2012. View Article : Google Scholar : PubMed/NCBI
20	Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Büchner T, Wörmann B, Hiddemann W, et al: Identification of the adapter molecule MTSS1 as a potential oncogene-specific tumor suppressor in acute myeloid leukemia. PLoS One. 10:e01257832015. View Article : Google Scholar : PubMed/NCBI
21	Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hänzelmann S, Gusmao EG, Kintsler S, Braunschweig T, et al: MTSS1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia. 30:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zhong J, Shaik S, Wan L, Tron AE, Wang Z, Sun L, Inuzuka H and Wei W: SCF β-TRCP targets MTSS1 for ubiquitination-mediated destruction to regulate cancer cell proliferation and migration. Oncotarget. 4:2339–2353. 2013. View Article : Google Scholar : PubMed/NCBI
23	Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, et al: Revised International Staging System for Multiple Myeloma: A report from international myeloma working group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI
24	Yan H, Wu QL, Sun CY, Ai LS, Deng J, Zhang L, Chen L, Chu ZB, Tang B, Wang K, et al: piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma. Leukemia. 29:196–206. 2015. View Article : Google Scholar : PubMed/NCBI
25	Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, Zhang L and Hu Y: miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis. 34:426–435. 2013. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Tang W, Su G, Li J, Liao J, Chen S, Huang C, Liu F, Chen Q and Ye Y: Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear f7actor-κB in vitro and in vivo. Int J Oncol. 45:995–1010. 2014. View Article : Google Scholar : PubMed/NCBI
28	Rajan AM and Rajkumar SV: Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 5:e3652015. View Article : Google Scholar : PubMed/NCBI
29	Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, et al: A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC myeloma IX trial. Leukemia. 26:349–355. 2012. View Article : Google Scholar : PubMed/NCBI
30	Drach J, Ackermann J, Fritz E, Krömer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, et al: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 92:802–809. 1998.PubMed/NCBI
31	Manasanch EE, Korde N, Zingone A, Tageja N, Fernandez de Larrea C, Bhutani M, Wu P, Roschewski M and Landgren O: The proteasome: Mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leuk Lymphoma. 55:1707–1714. 2014. View Article : Google Scholar : PubMed/NCBI
32	Deshaies RJ: Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 12:942014. View Article : Google Scholar : PubMed/NCBI
33	Ang XL and Wade Harper J: SCF-mediated protein degradation and cell cycle control. Oncogene. 24:2860–2870. 2005. View Article : Google Scholar : PubMed/NCBI
34	Yi YW, Kang HJ, Bae EJ, Oh S, Seong YS and Bae I: β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells. Exp Mol Med. 47:e1432015. View Article : Google Scholar : PubMed/NCBI
35	Zhang S and Qi Q: MTSS1 suppresses cell migration and invasion by targeting CTTN in glioblastoma. J Neurooncol. 121:425–431. 2015. View Article : Google Scholar : PubMed/NCBI
36	Shi W, Hasimu G, Wang Y, Li N, Chen M and Zhang H: MTSS1 is an independent prognostic biomarker for survival in intrahepatic cholangiocarcinoma patients. Am J Transl Res. 7:1974–1983. 2015.PubMed/NCBI